Justin P.D. Wilcox

I'll research this attorney before drafting.

Let me verify a few specific case results and PTAB activity.

Let me verify a couple more items — the COVID vaccine case and PTAB/IPR footprint.

Justin P.D. Wilcox — Desmarais LLP (Washington, D.C. / New York)

Focus areas. Wilcox is a trial and appellate patent litigator whose docket spans both life sciences and electronics. His Desmarais profile lists small molecules, nucleic acids, semiconductors, fintech, mobile devices, medical devices, internet communications protocols, video coding, and telecommunications; an earlier version of the same bio adds video coding, social networking, bionic prosthetics, smartphones, and VoIP. His practice also covers trade secret misappropriation, antitrust, and technology-related contract disputes, plus settlement/licensing negotiation. He is not a single-technology specialist — the through-line is complex, technically dense infringement and trade secret litigation rather than any one standards or industry vertical.

Side preference. The tracked dataset here contains only one appearance (plaintiff side, trial counsel, Desmarais), and the underlying case is unidentified, so it is a very thin basis for characterizing his practice. Public records show a genuinely mixed book. Defense-side work for operating companies includes Cisco, Facebook/Meta, HTC (ITC), Broadsoft, Cloud9 Technologies, and Motorola Mobility (SEVEN Networks v. Motorola Mobility, N.D. Tex.); plaintiff/patent-owner-side work includes ViiV Healthcare/Shionogi, GSK, Enzo Life Sciences, Multimedia Patent Trust, and Ronald A. Katz Technology Licensing. That is, he is neither a dedicated defense counsel nor an NPE-focused plaintiffs' lawyer — though the assertion-side matters (Katz, Enzo, Multimedia Patent Trust) are a meaningful part of the record.

Firm and notable matters. He has been a partner at Desmarais LLP since 2012 and relocated to open and manage the firm's Washington, D.C. office; before that he was an associate at Cooley LLP in Reston, Virginia (2006–2012) and at Kirkland & Ellis in D.C. (2004–2006), where he worked with firm founder John Desmarais. His most prominent result is ViiV Healthcare / Shionogi v. Gilead Sciences (D. Del.), the dolutegravir/Biktarvy case he co-led with John Desmarais, which settled in February 2022 for a $1.25 billion upfront payment plus a 3% royalty on U.S. Biktarvy sales through patent expiry in 2027 — reported as one of the largest patent settlements on record, and resolving parallel actions in eight other countries. He also led the Cisco defense in Straight Path IP Group v. Cisco (N.D. Cal.), winning summary judgment of noninfringement three months after taking over the case (aff'd, 748 F. App'x 1027 (Fed. Cir. 2019)), then a $1.9 million § 285 fee award that he defended and argued on appeal (Fed. Cir. Rule 36 affirmance, May 2021). He represents GSK in its mRNA vaccine infringement actions against Pfizer/BioNTech and Moderna (D. Del.) and in GSK's intervention in CureVac v. BioNTech/Pfizer.

PTAB and credentials. His documented PTAB footprint is as backup counsel for patent owner Enzo Life Sciences in a group of nucleic acid IPRs (including IPR2016-00820), where he was admitted pro hac vice and argued at the oral hearing; nothing in the public record indicates he is a routine IPR/PGR petitioner-side practitioner — his center of gravity is district court and Federal Circuit work. He clerked for then-Judge John G. Roberts Jr. on the D.C. Circuit (2003–04) and holds a J.D. with honors from George Washington University Law School (2003), where he was Editor-in-Chief of the George Washington Law Review, and a B.S. in mechanical engineering from West Point (1995). Admitted in Virginia (2003), D.C. (2007), and New York (2013), and before the Federal Circuit and Ninth Circuit; recognized in Best Lawyers (Litigation–Patent) since 2023 and as an IAM Patent 1000 / IP Stars honoree.